Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,270 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04661150 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | completed | Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04868162 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 70 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 |
| clinicaltrials |
| NCT05877820 | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | completed | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02968810 | Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | completed | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05816785 | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | completed | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06390059 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 84 | NovoCure Ltd.INDUSTRY | 4 | Sep 4, 2026 | clinicaltrials |
| NCT04493060 | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | completed | Phase 2 | 22 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06470750 | Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | completed | — | 75 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802977 | Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia | completed | Phase 1 | 10 | University of California, DavisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02880007 | Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer(TRIDICOL) | completed | Phase 2 | 48 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04209686 | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | completed | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05909904 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 160 | BeiGeneINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT05935995 | Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination(HISTOBLOC) | completed | N/A | 42 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03948724 | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology(EDHITO) | completed | N/A | 412 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03457948 | Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases | completed | Phase 2 | 32 | Nicholas Fidelman, MDOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04090710 | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer(CYTOSHRINK) | completed | Phase 2 | 66 | Ontario Clinical Oncology Group (OCOG)OTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT05168631 | Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors(NET) | completed | — | 88 | Latin American Cooperative Oncology GroupOTHER | 4 | Aug 28, 2026 | clinicaltrials |
| NCT05328765 | A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection(ACTION HIV) | completed | — | 369 | Latin American Cooperative Oncology GroupOTHER | 5 | Aug 28, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04943445 | Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers(SMART-KEY) | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06234488 | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | completed | — | 125 | Medical College of WisconsinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06478043 | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791329 | Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer(GastroPET) | completed | Phase 2 | 144 | Masaryk Memorial Cancer InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT03644186 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)(TOUCH) | completed | Phase 2 | 147 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 26, 2026 | clinicaltrials |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | completed | Phase 3 | 2,431 | National Cancer Institute (NCI)NIH | 5 | Aug 25, 2026 | clinicaltrials |
| NCT02206360 | Pancreatic Cancer Early Detection Program(PCEDP) | completed | — | 181 | White Plains HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03304639 | Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05997056 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | completed | Phase 2 | 12 | Aadi Bioscience, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT01882933 | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma(GASTRICHIP) | completed | Phase 3 | 367 | Hospices Civils de LyonOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 24, 2026 | clinicaltrials |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT07781319 | Early Gastric Cancer in the Spanish EURECCA Registry | completed | — | 600 | Corporacion Parc TauliOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT03012789 | Surgical Intervention and the NETest(NETest_Sx) | completed | N/A | 30 | Wren Laboratories LLCINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778615 | Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features | completed | — | 34 | Sohag UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06114082 | TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma(IDADOX) | completed | Phase 2 | 128 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05545150 | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study | completed | Phase 2 | 113 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials